This clinical trial tests the effect of radiofrequency ablation (RFA) in treating patients with parathyroid cancer that has come back after a period of improvement (recurrent) and that has spread from where it first started (primary site) to a limited number of other places in the body (oligometastatic). RFA is a procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). RFA may be safe, tolerable, and/or effective in treating patients with recurrent oligometastatic parathyroid cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07475780.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Thinh Vu
Phone: 713-775-3901
PRIMARY OBJECTIVE:
I. Evaluate treatment response of RFA of recurrent parathyroid carcinoma (PC) by means of longitudinal monitoring patient serum calcium level and parathyroid hormone (PTH).
SECONDARY OBJECTIVES:
I. Evaluate the sonographic features of the recurrent PC induced by RFA.
II. Evaluation of procedure-related complications.
III. Disease free survival until recurrence of hypercalcemia.
OUTLINE:
Patients undergo RFA on study. Additionally, patients undergo sestamibi scan, four dimensional computed tomography (4DCT), ultrasound, and blood sample collection throughout the study.
After completion of study treatment, patients are followed up at days 1 and 3-5, and at 1, 6, and 12 months.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorThinh Vu